ACADIA Pharmaceuticals Inc. (ACAD) AI Stock Analysis

ACADIA Pharmaceuticals Inc. is a biopharmaceutical enterprise headquartered in San Diego, California, developing therapies for central nervous system (CNS) disorders and rare diseases. Its flagship commercial product is NUPLAZID (pimavanserin), approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes Trofinetide for Rett syndrome, partnered with Neuren Pharmaceuticals Limited, and pimavanserin in Phase III ADVANCE-2 testing for negative symptoms of schizophrenia. The company is also developing ACP-204 for Alzheimer's disease psychosis and collaborates with Stoke Therapeutics, Inc. on RNA-based medicines for severe genetic CNS disorders.

Revenue grew from $484.1M in FY2021 to $1.07B in FY2025, demonstrating a 5-year revenue CAGR of 19.4%. Operating performance shifted from an operating margin of -35.2% in FY2021 to 24.1% in FY2024 and 9.8% in FY2025. Net income reached $391.0M in FY2025, up from $226.5M in FY2024 and net income of -$216.0M in FY2022. Over the trailing twelve months, revenue stands at $1.14B with a profit margin of 33.4% and an operating margin of 12.3%. For the latest quarter ending June 30, 2026, quarterly revenue grew 16.4% year-over-year while quarterly earnings expanded 13.3%.

As of June 30, 2026, ACADIA held $956.5M in cash and short-term investments alongside total debt of $73.9M, producing net cash of $882.6M. The company shows solid liquidity with a current ratio of 3.39 and a debt-to-equity ratio of 0.06 on shareholders' equity of $1.31B. Free cash flow was $105.1M in FY2025, supported by modest capital expenditures of $4.7M. The 5-year share count increased by 7.5%.

At a last close of $19.12 on October 16, 2026, ACADIA trades at a trailing price-to-earnings ratio of 8.6x, compared to 24.6x for the median of its US-listed Healthcare peers. However, its forward P/E of 25.2x and EV to EBITDA of 35.5x trade above the peer group medians of 17.3x and 12.0x, respectively. The stock's price-to-sales multiple is 2.9x versus the peer median of 4.1x. Over the past year, ACAD shares fell 7.3%, lagging the S&P 500 return of 16.8%, and its 5-year return of 9.2% trailed the index return of 83.0%.

Wall Street coverage consists of 10 Strong Buy, 4 Buy, 5 Hold, 0 Sell, and 1 Strong Sell recommendations. The mean price target is $30.53, representing a 59.7% premium over the last close of $19.12. For FY2026, analysts estimate revenue of $1.27B and EPS of $0.59, representing an earnings decline of 28.3%. For FY2027, 13 analysts forecast revenue of $1.43B and EPS growth of 54.7% to $0.92. ACADIA exceeded earnings estimates in 2 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of ACADIA Pharmaceuticals Inc. (ACAD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACAD income statement, ACAD balance sheet, ACAD key metrics, ACAD analyst forecast, ACAD chart. See the ACAD stock overview for the latest quote and news.